---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-041877"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2026-09-09T12:00:19+00:00"
generated_at: "2026-09-09T12:05:26.558824+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma completes dosing in Phase 1b norovirus challenge study for CDI-988

## Summary
- Last subject dosed in Phase 1b norovirus challenge study (NCT07198139) evaluating CDI-988 as preventive and treatment.
- No serious adverse events reported to date; CDI-988 previously safe at 1200 mg dose in Phase 1.
- Preliminary efficacy results expected late 2026 or early 2027.
- Study at Emory University enrolled healthy adults 18-49 infected with GII.2 (Snow Mountain Virus) strain.
- CDI-988 is first oral antiviral for norovirus, designed to inhibit replication in all known strains.

## SEC filing metadata
- accession: 0001493152-26-041877
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2026-09-09T12:00:19+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315226041877/0001493152-26-041877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315226041877/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-041877
- JSON: https://secwatch.observer/filing/0001493152-26-041877.json
- Plain text: https://secwatch.observer/filing/0001493152-26-041877.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.